NDRA_OUT_1 [2025-04-17 11:20:48 -0400] 4517 Bytes | 1155 tokens | Cum: 1155 tkns (14.44% of 8k)
==========================================================================

We need a winner today and it's already 11:20:47 AM on Thu Apr 17, 2025 -0400 ... So let's find out if ENDRA Life Sciences (NDRA) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 5.1100 up from 3.3500. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: ENDRA Life Sciences (NDRA)
IPO: 2017-06-28 (7 Years Ago)
Market Cap: $1,883,414
Shares Outstanding: 560,000
Industry: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange: XNAS
Description: ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Here’s a list of headlines for ENDRA Life Sciences:

Mar-31-25 08:05AM - ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies
Mar-31-25 08:05AM 08:00AM - ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update
Jan-28-25 12:00PM - What Makes ENDRA Life Sciences (NDRA) a New Strong Buy Stock
Nov-22-24 08:00AM - ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nov-15-24 09:24AM - ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Nov-12-24 08:00AM - Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting 2024
Nov-06-24 08:00AM - ENDRA Life Sciences Further Strengthens TAEUS Platform Intellectual Property with Issuance of 17th European Patent
Oct-22-24 08:00AM - ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-06-18T10:28:00Z - What 3 Factors Impact Penny Stocks Prices the Most
B2 - 2024-06-06T10:35:00Z - How Trading Penny Stocks Has Changed in 2024
B3 - 2024-04-01T12:08:35Z - Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
B4 - 2023-12-26T18:48:21Z - Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B5 - 2023-09-15T16:40:52Z - Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B6 - 2023-09-15T11:54:25Z - Why Volcon Shares Are Trading Lower By 19%; Here Are 20 Stocks Moving Premarket

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for ENDRA Life Sciences (NDRA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

NDRA_OUT_3 [2025-04-17 11:20:51 -0400] 1003 Bytes | 294 tokens | Cum: 1451 tkns (18.14% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-14T16:16:05Z - NDRA stock touches 52-week low at $3.05 amid sharp annual decline By Investing.com...
A2 - 2025-04-14T16:16:05Z - NDRA stock touches 52-week low at $3.05 amid sharp annual decline By Investing.com...
A3 - 2025-04-10T17:06:03Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - Brainstorm Cell (NASDAQ:BCLI), Bio-Rad...
A4 - 2025-04-10T12:07:48Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Brainstorm Cell (NASDAQ:BCLI), Ensys...
A5 - 2025-04-09T21:05:58Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - Autolus Therapeutics (NASDAQ:AUTL...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NDRA_OUT_5 [2025-04-17 11:20:52 -0400] 1181 Bytes | 323 tokens | Cum: 1776 tkns (22.20% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**NDRA stock touches 52-week low at $3.05 amid sharp annual decline By Investing.com**Date: 2025-04-14Source: {'uri': 'uk.investing.com', 'dataType': 'news', 'title': 'Investing.com UK'}URL: https://uk.investing.com/news/company-news/ndra-stock-touches-52week-low-at-305-amid-sharp-annual-decline-93CH-4029761In a challenging year for ENDRA Life Sciences (NASDAQ:NDRA) Inc., the company's stock has plummeted to a 52-week low, trading at $3.05. According to InvestingPro data, the company's market capitalization has shrunk to just $1.89 million, with a concerning EBITDA of -$10.77 million in the last twelve months. This latest price point underscores a tumultuous period for the medical device company, which has seen its stock value erode by an alarming 99.27% over the past year. While the company maintains a strong current ratio of 5.67 and holds more cash than debt, InvestingPro analysis

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_7 [2025-04-17 11:20:53 -0400] 1181 Bytes | 251 tokens | Cum: 2029 tkns (25.36% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): indicates a WEAK overall financial health score. Investors have watched with concern as ENDRA, which specializes in thermo-acoustic enhanced ultrasound technologies, grapples with market pressures and internal challenges that have significantly impacted its share price and market confidence. The company is scheduled to report its next earnings on May 13, 2025, which could provide crucial insights into its turnaround potential.

In other recent news, ENDRA Life Sciences is shifting its strategic focus to the metabolic health market, particularly targeting diseases treated with glucagon-like peptide-1 (GLP-1) drugs. The company aims to develop and market its TAEUS system for early detection and management of metabolic diseases, addressing the significant demand for liver health monitoring tools. ENDRA is refining the TAEUS design and collecting clinical data to prepare for a future FDA De

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_9 [2025-04-17 11:20:56 -0400] 1025 Bytes | 201 tokens | Cum: 2232 tkns (27.90% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): Novo regulatory filing. This strategic pivot includes targeting new customer segments such as pharmaceutical companies and various medical practices. The company is enhancing the TAEUS Liver device with artificial intelligence and integrating thermo-acoustic and ultrasound technologies to improve accuracy and reduce costs. Additionally, ENDRA plans to introduce a subscription-based sales model to facilitate customer uptake. The company is also broadening the applicability of its technology to include temperature monitoring for ablation therapies and vascular and tissue perfusion. ENDRA's developments aim to provide reliable diagnostic tools for metabolic syndrome and chronic conditions, potentially improving public health outcomes.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_11 [2025-04-17 11:20:58 -0400] 1093 Bytes | 286 tokens | Cum: 2520 tkns (31.50% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto included elsewhe...

S2 - 2024-11-22 8-K Item 7.01 Regulation FD Disclosure

On November 21, 2024, ENDRA Life Sciences Inc. (the Company) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq), informing the Company that it has regained compliance with the minimum ...

S3 - 2024-11-19 10-Q PART I - FIN INFO

Item 1. Fin Stmnts

ENDRA Life Sciences Inc.

Condensed Cons Balance Sheets

September 30,

December 31,

Assets

Curr Assets

(Unaudited)

Cash

$ 4,745,187

$ 2,833,907

Prepaid expenses

217,120

198,905

Total ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NDRA_OUT_13 [2025-04-17 11:20:59 -0400] 1181 Bytes | 241 tokens | Cum: 2763 tkns (34.54% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this Annual Report. This discussion and analysis contain forward-looking statements that are based on our managements current beliefs and assumptions, which statements are subject to substantial risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those discussed in Risk Factors in Item 1A of this Annual Report. Please also see Cautionary Note Regarding Forward-Looking Statements and Risk Factor Summary at the beginning of this Annual Report.

Overview

We are developing a thermo-acou

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_15 [2025-04-17 11:21:00 -0400] 1181 Bytes | 255 tokens | Cum: 3020 tkns (37.75% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): stic medical device designed specifically for accurate liver fat measurement for metabolic disease detection and management and GLP-1 drug eligibility and management. Our goal is to create the next-generation enhanced ultrasound technology platform designed to establish key biomarkers for metabolic diseases management and emerging GLP-1 therapies.

Our business model will primarily be a low barrier-to-entry, multi-year, subscription-based business model with monthly recurring revenue (MRR), while also offering a traditional product sale with annual upgrade and maintenance fees. These sales are expected to be made by a direct sales force to four markets:

##TABLE_START

1.

Pharmaceutical Companies and Clinical Research Organizations (CROs) - to assist them in the efficient screening monitoring subjects for new GLP-1, NASH/MASH and Insulin Sensitizers clinical trials.

2.

High-End Pri

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_17 [2025-04-17 11:21:00 -0400] 1181 Bytes | 242 tokens | Cum: 3264 tkns (40.80% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): mary Care Clinics - to assist them screening patients for obesity, diabetes and liver disease as well as monitor response to lifestyle changes and drug therapies.

3.

Bariatric and Metabolic Clinics - for obesity and other metabolic diseases detection and therapies response monitoring

4.

Primary Internal Medicine at Large - to screen patients for obesity, diabetes and liver disease and monitor response to lifestyle change and drug therapy

##TABLE_END

Each of our solutions will require regulatory approvals before we are able to sell or license the application. Based on certain factors, such as the installed base of ultrasound systems, availability of other imaging technologies, such as CT and MRI, economic strength and applicable regulatory requirements, we intend to seek initial approval of our applications for sale in the European Union and the United States.

Financial Operations

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_19 [2025-04-17 11:21:01 -0400] 1181 Bytes | 245 tokens | Cum: 3511 tkns (43.89% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): Overview

Revenue

No revenue has been generated by our TAEUS technology, which we have not commercially sold as of December 31, 2024.

##TABLE_START 46

##TABLE_END

Research and Development Expenses

Our research and development expenses primarily include wages, fees and equipment for the development of our TAEUS technology platform. Additionally, we incur certain costs associated with the protection of our products and inventions through a combination of patents, licenses, applications and disclosures. These costs and expenses include:

##TABLE_START

employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead related expenses and travel-related expenses for our research and development personnel;

expenses incurred under agreements with CROs, contract manufacturing organi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_21 [2025-04-17 11:21:02 -0400] 1181 Bytes | 247 tokens | Cum: 3760 tkns (47.00% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): zations (CMOs) as well as consultants that support the implementation of our clinical and non-clinical studies;

manufacturing and packaging costs in connection with conducting clinical trials;

formulation, research and development expenses related to our TAEUS technology; and

costs for sponsored research.

##TABLE_END

We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of TAEUS and pursue FDA approval. At this time, due to the inherently unpredictable nature of clinical development and regulatory approvals, we are unable to estimate with certainty the costs we will incur and the timelines we will require in our continued development efforts.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of headcount and consulting costs, and marketing and tradeshow expenses. Currently, our sales and m

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_23 [2025-04-17 11:21:03 -0400] 790 Bytes | 173 tokens | Cum: 3935 tkns (49.19% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): arketing efforts are primarily business development - generating awareness through meetings with research institutions, our website and attendance of key industry meetings and conferences. As of December 31, 2024, we had a full-time sales engineer in France and a part-time, contracted, business development executive in Germany. Upon FDA approval, we will expand our sales marketing efforts, primarily by adding a direct sales force and related expenses and costs.

General and Administrative Expenses ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NDRA_OUT_25 [2025-04-17 11:21:18 -0400] 5879 Bytes | 1535 tokens | Cum: 5472 tkns (68.40% of 8k)
==========================================================================

This is our set of metrics for ENDRA Life Sciences.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-------------------------+
| Volume: 36,813 | Perf Month: -1.44% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+-------------------------+
| Avg Volume: 38.27K | Perf Quarter: -34.40% | Short Float: 5.64% | ROE: -280.02% |
+--------------------+-----------------------+------------------------+-------------------------+
| Rel Volume: 3.57 | Index: - | Short Ratio: 0.83 | ROI: -377.58% |
+--------------------+-----------------------+------------------------+-------------------------+
| RSI (14): 49.22 | Market Cap: 2.18M | Short Interest: 0.03M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-------------------------+
| ATR (14): 0.60 | Shs Outstand: 0.56M | Beta: 0.14 | EPS Surprise: -1047.80% |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA20: -2.44% | Shs Float: 0.56M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA50: -7.28% | Inst Own: 0.14% | Sales past 5Y: 0.00% | Earnings: Mar 31 BMO |
+--------------------+-----------------------+------------------------+-------------------------+
| SMA200: -86.02% | Insider Own: 0.02% | Employees: 21 | |
+--------------------+-----------------------+------------------------+-------------------------+
| Perf Week: -1.52% | Insider Trans: 0.00% | Debt/Eq: 0.23 | |
+--------------------+-----------------------+------------------------+-------------------------+

The next section covers any insider trading by ENDRA Life Sciences officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -4013825.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 5.096
Average Volume: 94982.13
30-Day High: 5.096
30-Day Low: 3.1

[Detailed Financials: Q2 2024]
- Total Assets: $10,442,529.0
- Total Liabilities: $1,448,588.0
- Total Equity: $8,993,941.0
- Current Assets: $6,713,474.0
- Current Liabilities: $1,350,167.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $5,266,031.0

[Detailed Financials: Q1 2024]
- Total Assets: $5,060,701.0
- Total Liabilities: $1,362,529.0
- Total Equity: $3,698,172.0
- Current Assets: $1,270,522.0
- Current Liabilities: $1,216,704.0

[Income Statement: Q1 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $-1,699,206.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of ENDRA Life Sciences (NDRA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about ENDRA Life Sciences.

2) MARKET_SCORE[]
This conversation was initiated because NDRA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for NDRA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, NDRA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect NDRA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of ENDRA Life Sciences.

11) ETHICAL_RATING[]
Rate ENDRA Life Sciences’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of ENDRA Life Sciences.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

NDRA_IN_27 [2025-04-17 11:21:18 -0400] 126 Bytes | 29 tokens | Cum: 5704 tkns (71.30% of 8k)
==========================================================================

====================================
[2025-04-17 11:21:18] # Analysis Completed
Elapsed Time: 30.53 seconds